ArticleItalian journal of pediatrics2026
Epidemiological trends of multidrug-resistant organisms in a tertiary-care pediatric hospital, 2017-2023.
Article in Italian journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SIOOTAntibiotics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntimicrobial resistance (AMR) is a growing global threat, particularly for children under 5 years. This study is aimed to investigate temporal trends and describe the epidemiological characteristics of MDR bacteria isolated in hospitalized children from 2017 to 2023 in an academic children's hospital in Italy.
methodsWe included all bacterial isolates obtained from blood or cerebrospinal fluid (CSF) cultures collected from pediatric patients evaluated in both inpatient settings and the Emergency Department between 1 January 2017 and 31 December 2023. The study included the main ESKAPE pathogens (including Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa) and other relevant MDROs such as Escherichia coli. Data were extracted from the hospital microbiology data warehouse, and resistance proportions were calculated as MDR isolates over total isolates for each pathogen. Associations between year, patient characteristics, ward type, and MDRO infections were evaluated using univariable and multivariable logistic regression; trends over time were evaluated using the Cochrane-Armitage test for categorical variables.
resultsOut of 51,886 blood or CSF cultures, 1,528 (2.9%) were positive for microorganisms of interest, and 211 (13.8%) were MDROs. The highest resistance proportions were observed in Carbapenems-Resistant Pseudomonas Aeruginosa/Pseudomonas Aeruginosa (CRPA/PA, 52.8%), followed by Methicilln-Resistant Staphylococcus Aureus/Staphylococcus Aureus (MRSA/SA, 36.7%), Carbapenem-Resistant Klebsiella Pneumoniae/Klebsiella Pneumoniae (CRKP/KP, 12.6%), and Vancomycin-Resistant Enterococcus (VRE)/Enterococcus (VRE/E, 11.5%). Significant reductions were recorded for MRSA/SA (43.5% in 2017 to 25.7% in 2023; p = 0.001) and CRPA/PA (85.0% to 47.1%; p < 0.001), while CRKP/KP and VRE/E showed no significant temporal trends. Neonatology and PICU showed higher odds for MRSA isolation (p < 0.001) compared to medical wards. Onco-hematology displayed an adjusted OR of 3.0 (95% CI: 1.2-7.7) for VRE. Year was independently associated with CRPA, with adjusted ORs of 0.03 and 0.14 in 2020 and 2021 (p < 0.01) compared to 2017.
conclusionsUnderstanding local AMR patterns remains essential for guiding empirical therapy across heterogeneous hospital settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.